NEW YORK (Reuters) - If there was any doubt that Genentech Inc was caught by surprise by Roche’s move to acquire the remaining stake in the biotechnology giant it doesn’t already own, one need only look at recent executive stock transactions.
NEW YORK (Reuters) - If there was any doubt that Genentech Inc was caught by surprise by Roche’s move to acquire the remaining stake in the biotechnology giant it doesn’t already own, one need only look at recent executive stock transactions.
